Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.a

Pulmonary edema, noncardiogenic (NCPE)

Publications

Bevill BT, Argula RG, Gilkeson GC, Kim NH

A Man with Severe Pulmonary Hypertension and Right Ventricular Failure.

Annals of the American Thoracic Society. 2018;15(12):1472-1476

Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Annals of internal medicine. 2000;132(6):425-34

Gugnani MK, Pierson C, Vanderheide R, Girgis RE

Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis.

Arthritis and rheumatism. 2000;43(3):699-703

Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, Parent F, Simonneau G

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

The European respiratory journal. 1999;13(6):1351-6

Humbert M, Maître S, Capron F, Rain B, Musset D, Simonneau G

Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.

American journal of respiratory and critical care medicine. 1998;157(5 Pt 1):1681-5